NFKB1 and metabolic dysfunction-associated steatohepatitis: The therapeutic efficacy of HDP in NASH may be associated with regulation of NF‐κB and lipid metabolism‐related pathways via AA metabolism, glycine‐serine‐threonine metabolism, as well as steroid hormone biosynthesis (Figure 6).